CNS Pharmaceuticals (NASDAQ: CNSP) Conducts Public Offering Funding Effort, Appears in Syndicated Broadcast on Brain Cancer Drug Advances
Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancersCNS’s Phase 2 trials are scheduled to begin during Q1 of 2021, building on a Phase 1 trial in which 44 percent of patients saw improvement and one patient has survived…